MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement